WEBULL

Assessing Pfizer (PFE) Valuation As Recent Trading Momentum Shows Signs Of Slowing

Simply Wall St · 6d ago

Why Pfizer is on investors’ radar today

Pfizer (PFE) is back in focus after recent trading left the shares with a small 1 day gain and a modest move higher over the past week, contrasting with weaker returns over the past month and the past 3 months.

See our latest analysis for Pfizer.

While Pfizer’s share price is currently at $25.18, the 30 day share price return of 3.27% and 90 day share price return of 4.15% sit against a 3 year total shareholder return of 38.10% and 5 year total shareholder return of 14.92%, which indicates that recent momentum may be slowing as investors reassess growth prospects and risks following a period of weaker performance.

If Pfizer has you thinking more broadly about large healthcare names, this may be a useful moment to scan other healthcare stocks that might fit your portfolio goals.

With Pfizer shares around $25.18, an intrinsic discount estimate of 60% and a value score of 5, the key question is whether this reflects a genuine pricing opportunity or whether the market is already accounting for future growth.

Most Popular Narrative: 13.4% Undervalued

With Pfizer closing at $25.18 against a narrative fair value of $29.08, the story treats the current price as a discount worth unpacking.

Strategic business development and licensing (such as the 3SBio bispecific antibody deal and ongoing portfolio additions in high-value areas like oncology, immunology, and obesity) support revenue diversification and lifecycle management, mitigating the impact of patent expirations and increasing net margins via synergies and optimized product mix.

Read the complete narrative.

Curious what earnings trajectory, margin shift, and future P/E this narrative uses to describe Pfizer as undervalued? The full model spells out those assumptions in detail.

Result: Fair Value of $29.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this thesis can be knocked off course if regulatory pressure on drug pricing tightens or key obesity and oncology assets fail to deliver as analysts expect.

Find out about the key risks to this Pfizer narrative.

Build Your Own Pfizer Narrative

If you see the numbers differently or want to stress test your own assumptions, you can build a custom Pfizer story in just a few minutes by starting with Do it your way.

A great starting point for your Pfizer research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop at Pfizer, you could miss other opportunities, so take a few minutes to scan fresh ideas that might fit how you actually invest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.